The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
Br J Haematol
; 143(4): 589-92, 2008 Nov.
Article
en En
| MEDLINE
| ID: mdl-18764867
ABSTRACT
Hydroxycarbamide (HC), although a key drug therapy in sickle cell disease (SCD), does not result in a clinical response in all patients. Increases in fetal haemoglobin (HbF) and mean corpuscular volume of erythrocytes are standard clinical measures of HC efficacy in SCD. Genetic studies have determined that the majority of HbF regulation occurs outside the beta-globin locus. Approximately 30% of SCD patients have co-inherited alpha-thalassaemia resulting in hypochromic and microcytic erythrocytes. We provide data from 30 SCD patients (10 with alpha-thalassaemia) demonstrating that co-existing alpha-thalassaemia significantly affects several standard measures of HC efficacy in SCD.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Talasemia
/
Hidroxiurea
/
Anemia de Células Falciformes
/
Antidrepanocíticos
Tipo de estudio:
Clinical_trials
Límite:
Adolescent
/
Adult
/
Child
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Br J Haematol
Año:
2008
Tipo del documento:
Article
País de afiliación:
Reino Unido